All Stories

  1. Prevalence, clinical associations, and outcomes of pericarditis in systemic lupus erythematosus: insights from the University of Toronto Lupus Clinic

    Article • Rheumatology, December 2025, Oxford University Press (OUP)

    Dr. Zahi Touma

  2. Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies)

    Article • Seminars in Arthritis and Rheumatism, December 2025, Elsevier

    Dr. Zahi Touma, Dr. Dafna D Gladman

  3. Examining Self‐Reported Executive Function and Its Relationship to Patient‐Reported Outcomes and Disease‐Related Factors in Youth With Childhood‐Onset Lupus: A Cross‐Sectional Study

    Article • ACR Open Rheumatology, November 2025, Wiley

    Dr. Zahi Touma

  4. Testing the Possibility of Preventing Systemic Lupus Erythematosus

    Article • Arthritis & Rheumatology, November 2025, Wiley

    Dr. Zahi Touma

  5. Fine particulate matter air pollution and anti-nuclear antibodies

    Article • Rheumatology, October 2025, Oxford University Press (OUP)

    Dr. Zahi Touma

  6. Improving Mental Health Care for People With Systemic Lupus Erythematosus: Time to Take Action

    Article • The Journal of Rheumatology, October 2025, The Journal of Rheumatology

    Dr. Zahi Touma

  7. Membranous Lupus Nephritis: Too Little, Too Much!

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  8. Is antimalarial use associated with a reduced risk of LN in patients with SLE? Results from an inception cohort-based study

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  9. Venous thromboembolism in patients with lupus nephritis: frequency and risk factors—a cohort study

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  10. Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients?

    Article • Seminars in Arthritis and Rheumatism, August 2025, Elsevier

    Dr. Zahi Touma, Dr. Dafna D Gladman

  11. Differences in IgG Sialylation Distinguish Asymptomatic from Symptomatic Anti‐Nuclear Antibody Positive Individuals

    Article • Arthritis & Rheumatology, July 2025, Wiley

    Dr. Zahi Touma

  12. Comparative Analysis of Damage Accrual in Lupus Nephritis Stratified by Biological Sex

    Article • The Journal of Rheumatology, July 2025, The Journal of Rheumatology

    Dr. Zahi Touma, Dr. Dafna D Gladman

  13. A glossary of signs and symptoms of giant cell arteritis

    Article • Annals of the Rheumatic Diseases, July 2025, Elsevier

    Dr. Zahi Touma

  14. Comparison of Lupus Nephritis Onset Before and After Age 50: Effect on Presentation and Outcomes in an Inception Cohort

    Article • The Journal of Rheumatology, July 2025, The Journal of Rheumatology

    Dr. Zahi Touma, Dr. Dafna D Gladman

  15. Responsive and monophasic lupus nephritis: prevalence, associations, and outcomes

    Article • Rheumatology, April 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  16. Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis: Reply

    Article • Rheumatology, March 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  17. Identified genetic locus for longitudinal disease activity in adults with systemic lupus erythematosus

    Article • Rheumatology, February 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  18. Lived Education Experience of Young Adults With Childhood- and Adult-Onset Systemic Lupus Erythematosus: A Multicenter Canadian Qualitative Study

    Article • The Journal of Rheumatology, February 2025, The Journal of Rheumatology

    Dr. Zahi Touma

  19. The Lived Employment Experience of Young Adults with Childhood and Adult Onset Systemic Lupus Erythematosus: A Multicentre Canadian Qualitative Study

    Article • Arthritis Care & Research, January 2025, Wiley

    Dr. Zahi Touma

  20. Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?

    Article • RMD Open, January 2025, BMJ

    Dr. Zahi Touma

  21. Primary headache in SLE –systematic review and meta-analysis

    Article • Seminars in Arthritis and Rheumatism, December 2024, Elsevier

    Dr. Zahi Touma

  22. Interferon-α as a biomarker to predict renal outcomes in lupus nephritis

    Article • Lupus Science & Medicine, November 2024, BMJ

    Dr. Zahi Touma, Dr. Dafna D Gladman

  23. Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort

    Article • Lupus Science & Medicine, November 2024, BMJ

    Dr. Zahi Touma

  24. Impact of baseline proteinuria level on long-term outcomes in lupus nephritis

    Article • Rheumatology, October 2024, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  25. Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as...

    Article • ACR Open Rheumatology, September 2024, Wiley

    Dr. Zahi Touma

  26. Short and Long-Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

    Article • Rheumatology, August 2024, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  27. Modelling long-term outcomes for patients with systemic lupus erythematosus

    Article • Seminars in Arthritis and Rheumatism, July 2024, Elsevier

    Dr. Zahi Touma

  28. Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard‐of‐Care Management of Systemic Lupus Erythematosus in Canada

    Article • ACR Open Rheumatology, June 2024, Wiley

    Dr. Zahi Touma

  29. Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis

    Article • Lupus Science & Medicine, January 2024, BMJ

    Dr. Zahi Touma, Dr. Dafna D Gladman

  30. Different Immunologic Profiles are Associated with Distinct Clinical Phenotypes in Longitudinally Followed Systemic Lupus Erythematosus Patients

    Article • Arthritis & Rheumatology, December 2023, Wiley

    Dr. Zahi Touma, Dr. Dafna D Gladman

  31. More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus

    Article • The Journal of Rheumatology, November 2023, The Journal of Rheumatology

    Dr. Zahi Touma

  32. Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task f...

    Article • RMD Open, June 2023, BMJ

    Dr. Zahi Touma

  33. Correspondence on “relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus” by Chi Chiu Mok et al

    Article • Lupus, April 2023, SAGE Publications

    Dr. Zahi Touma

  34. Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus

    Article • Rheumatology, March 2023, Oxford University Press (OUP)

    Dr. Zahi Touma

  35. Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group

    Article • Lupus, March 2023, SAGE Publications

    Dr. Zahi Touma

  36. What is a response in randomised controlled trials in giant cell arteritis?

    Article • Annals of the Rheumatic Diseases, February 2023, BMJ

    Dr. Zahi Touma

  37. Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective

    Article • Lupus Science & Medicine, February 2023, BMJ

    Dr. Zahi Touma, Prof. Luís Sousa Ines

  38. Intraindividual Change in Cognitive Function Among Adults With Systemic Lupus Erythematosus: A Markov Analysis Over 7 Years

    Article • ACR Open Rheumatology, January 2023, Wiley

    Dr. Zahi Touma

  39. Genetics of Osteonecrosis in Children and Adults with Systemic Lupus Erythematosus

    Article • Rheumatology, January 2023, Oxford University Press (OUP)

    Dr. Zahi Touma

  40. Systemic lupus erythematosus phenotypes formed from machine learning with a specific focus on cognitive impairment

    Article • Rheumatology, November 2022, Oxford University Press (OUP)

    Dr. Zahi Touma

  41. Evaluating the Threshold Score for Classification of Systemic Lupus Erythematosus Using the EULAR/ACR Criteria

    Article • The Journal of Rheumatology, November 2022, The Journal of Rheumatology

    Dr. Zahi Touma

  42. A Review of Lupus Nephritis

    Article • The Journal of Applied Laboratory Medicine, August 2022, Oxford University Press (OUP)

    Dr. Zahi Touma

  43. Altered Balance of Pro-Inflammatory Immune Cells to T Regulatory Cells Differentiates Symptomatic From Asymptomatic Individuals With Anti-Nuclear Antibodies

    Article • Frontiers in Immunology, June 2022, Frontiers

    Dr. Zahi Touma

  44. Trajectories of depressive symptoms in systemic lupus erythematosus over time

    Article • Rheumatology, June 2022, Oxford University Press (OUP)

    Dr. Zahi Touma

  45. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

    Article • The Lancet Rheumatology, June 2022, Elsevier

    Dr. Zahi Touma, Prof. Luís Sousa Ines

  46. Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

    Article • Frontiers in Immunology, May 2022, Frontiers

    Dr. Zahi Touma

  47. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls

    Article • The Journal of Rheumatology, February 2022, The Journal of Rheumatology

    Dr. Zahi Touma

  48. What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?

    Article • Rheumatology, January 2022, Oxford University Press (OUP)

    Dr. Zahi Touma

  49. Herpes zoster in SLE: prevalence, incidence and risk factors

    Article • Lupus Science & Medicine, January 2022, BMJ

    Dr. Zahi Touma

  50. Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus

    Article • Lupus, December 2021, SAGE Publications

    Dr. Zahi Touma

  51. Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management

    Article • Drugs & Aging, December 2021, Springer Science + Business Media

    Dr. Zahi Touma

  52. Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus

    Article • Seminars in Arthritis and Rheumatism, December 2021, Elsevier

    Dr. Zahi Touma

  53. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2

    Article • Seminars in Arthritis and Rheumatism, December 2021, Elsevier

    Dr. Zahi Touma

  54. Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematous

    Article • Lupus, November 2021, SAGE Publications

    Dr. Zahi Touma

  55. Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus

    Article • Lupus Science & Medicine, October 2021, BMJ

    Dr. Zahi Touma

  56. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

    Article • Rheumatology, September 2021, Oxford University Press (OUP)

    Dr. Zahi Touma

  57. Understanding COVID‐19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Population‐based analysis of SARS‐CoV‐2 Testing

    Article • Arthritis Care & Research, September 2021, Wiley

    Dr. Zahi Touma

  58. Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Whittall Garcia et al

    Article • Annals of the Rheumatic Diseases, August 2021, BMJ

    Dr. Zahi Touma

  59. Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review

    Article • Seminars in Arthritis and Rheumatism, August 2021, Elsevier

    Dr. Zahi Touma

  60. Systemic Lupus Erythematosus: The Next Generation of Ideas and Scientists

    Article • Rheumatic Disease Clinics of North America, August 2021, Elsevier

    Dr. Zahi Touma

  61. Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review

    Article • Lupus, July 2021, SAGE Publications

    Dr. Zahi Touma

  62. WHAT ARE THE DOMAINS AND OUTCOME MEASURES USED IN THE EXISTING NEUROPSYCHIATRIC SYSTEMATIC LUPUS ERYTHEMATOSUS LITERATURE?

    Article • Rheumatology, July 2021, Oxford University Press (OUP)

    Dr. Zahi Touma

  63. Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody–positive individuals

    Article • Rheumatology, June 2021, Oxford University Press (OUP)

    Dr. Zahi Touma

  64. Consideration of Fibromyalgia in the Assessment and Treatment of SLE

    Article • Current Treatment Options in Rheumatology, June 2021, Springer Science + Business Media

    Dr. Zahi Touma

  65. Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group

    Article • Seminars in Arthritis and Rheumatism, June 2021, Elsevier

    Dr. Zahi Touma, Dr. Saurab Sharma, Ph.D., Dr Win Min Oo

  66. Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials

    Article • Rheumatic Disease Clinics of North America, June 2021, Elsevier

    Dr. Zahi Touma

  67. POS0050 ARE PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) MORE LIKELY TO RECEIVE COVID-19 TESTS AND TEST POSITIVE FOR SARS-COV-2? A MATCHED POPULATION-BASED STUDY

    Article • Annals of the Rheumatic Diseases, May 2021, BMJ

    Dr. Zahi Touma

  68. OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) – A POPULATION-BASED STUDY

    Article • Annals of the Rheumatic Diseases, May 2021, BMJ

    Dr. Zahi Touma

  69. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus

    Article • Lupus Science & Medicine, May 2021, BMJ

    Dr. Zahi Touma

  70. P160 Clinical and sociodemographic associates of depression and anxiety in SLE

    Article • Rheumatology, April 2021, Oxford University Press (OUP)

    Dr. Zahi Touma

  71. Comment on: Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus: reply

    Article • Rheumatology, February 2021, Oxford University Press (OUP)

    Dr. Zahi Touma

  72. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

    Article • Annals of the Rheumatic Diseases, February 2021, BMJ

    Dr. Zahi Touma

  73. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

    Article • January 2021, Springer Science + Business Media

    Dr. Zahi Touma

  74. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE

    Article • Annals of the Rheumatic Diseases, January 2021, BMJ

    Dr. Zahi Touma

  75. Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years

    Article • Lupus, January 2021, SAGE Publications

    Dr. Zahi Touma

  76. Transfer from Pediatric to Adult Care Is Hardly Child’s Play

    Article • The Journal of Rheumatology, January 2021, The Journal of Rheumatology

    Dr. Zahi Touma

  77. Systemic lupus erythematosus symptom clusters and their association with patient‐reported outcomes and treatment: Analysis of real‐world data

    Article • Arthritis Care & Research, December 2020, Wiley

    Dr. Zahi Touma

  78. Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care

    Article • ACR Open Rheumatology, December 2020, Wiley

    Dr. Zahi Touma

  79. Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus

    Article • Arthritis Care & Research, November 2020, Wiley

    Dr. Zahi Touma

  80. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies

    Article • Rheumatology and Therapy, November 2020, Springer Science + Business Media

    Dr. Zahi Touma

  81. Measures of Anxiety in Rheumatic Diseases

    Article • Arthritis Care & Research, October 2020, Wiley

    Dr. Zahi Touma

  82. Measures of Cognition in Rheumatic Diseases

    Article • Arthritis Care & Research, October 2020, Wiley

    Dr. Zahi Touma

  83. Response to reviewer

    Article • Seminars in Arthritis and Rheumatism, October 2020, Elsevier

    Dr. Zahi Touma

  84. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Article • Annals of the Rheumatic Diseases, August 2020, BMJ

    Dr. Zahi Touma

  85. Cognitive function trajectories are associated with the depressive symptoms trajectories in systemic lupus erythematosus over time

    Article • Arthritis Care & Research, June 2020, Wiley

    Dr. Zahi Touma

  86. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review

    Article • Lupus Science & Medicine, June 2020, BMJ

    Dr. Zahi Touma

  87. THU0246 DIAGNOSTIC CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS

    Article • Annals of the Rheumatic Diseases, June 2020, BMJ

    Dr. Zahi Touma

  88. SAT0213 IMPACT OF FLARES ON HEALTHCARE RESOURCE USAGE AND PROS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

    Article • Annals of the Rheumatic Diseases, June 2020, BMJ

    Dr. Zahi Touma

  89. THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES

    Article • Annals of the Rheumatic Diseases, June 2020, BMJ

    Dr. Zahi Touma

  90. AB1170 THE IMPACT OF HIGH DISEASE ACTIVITY AS MEASURED BY SLEDAI AND DRUG BURDEN-ON HEALTHCARE UTILIZATION, QUALITY OF LIFE AND WORK PRODUCTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

    Article • Annals of the Rheumatic Diseases, June 2020, BMJ

    Dr. Zahi Touma

  91. Identifying a response for the systemic lupus erythematosus disease activity glucocorticoid index (SLEDAI‐2KG)

    Article • Arthritis Care & Research, May 2020, Wiley

    Dr. Zahi Touma

  92. Effect of TNF‐inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta‐analysis

    Article • International Journal of Rheumatic Diseases, May 2020, Wiley

    Dr. Zahi Touma

  93. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus

    Article • Rheumatology, March 2020, Oxford University Press (OUP)

    Dr. Zahi Touma

  94. Joint trajectories of disease activity, and physical and mental health-related quality of life in an inception lupus cohort

    Article • Rheumatology, March 2020, Oxford University Press (OUP)

    Dr. Zahi Touma

  95. Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus

    Article • Seminars in Arthritis and Rheumatism, October 2019, Elsevier

    Dr. Zahi Touma

  96. Associations among classification criteria items within systemic lupus erythematosus

    Article • Arthritis Care & Research, September 2019, Wiley

    Dr. Zahi Touma

  97. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Article • Arthritis & Rheumatology, August 2019, Wiley

    Dr. Zahi Touma

  98. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Article • Annals of the Rheumatic Diseases, August 2019, BMJ

    Dr. Zahi Touma

  99. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE

    Article • Rheumatology, June 2019, Oxford University Press (OUP)

    Dr. Zahi Touma

  100. Drs. Tayer-Shifman and Touma reply

    Article • The Journal of Rheumatology, June 2019, The Journal of Rheumatology

    Dr. Zahi Touma

  101. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis

    Article • Seminars in Arthritis and Rheumatism, June 2019, Elsevier

    Dr. Zahi Touma

  102. FRI0256 ASSESSING THE PREVALENCE AND USE OF VALIDATED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY METRICS IN REAL WORLD PRACTICE

    Article • June 2019, BMJ

    Dr. Zahi Touma

  103. FRI0178 CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR ASSOCIATED TREATMENTS

    Article • June 2019, BMJ

    Dr. Zahi Touma

  104. FRI0669 DEPRESSION AND ANXIETY AND THEIR CLINICAL CORRELATES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

    Article • June 2019, BMJ

    Dr. Zahi Touma

  105. THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS

    Article • June 2019, BMJ

    Dr. Zahi Touma

  106. AB0486 LACK OF CONSISTENT STANDARD OF CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN REAL WORLD

    Article • June 2019, BMJ

    Dr. Zahi Touma

  107. FRI0189 POOLED ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF BELIMUMAB IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS USING MULTI-COUNTRY DATA FROM THE OBSERVE STUDIES

    Article • June 2019, BMJ

    Dr. Zahi Touma

  108. THU0688 ASSESSMENT OF THE QRISK2, QRISK3, SLE CARDIOVASCULAR RISK EQUATION, FRAMINGHAM AND MODIFIED FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS

    Article • Annals of the Rheumatic Diseases, June 2019, Elsevier

    Dr. Zahi Touma

  109. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus

    Article • Arthritis Care & Research, May 2019, Wiley

    Dr. Zahi Touma

  110. The Assessment of Anxiety and Depression and its Associated Factors in SLE

    Article • Current Rheumatology Reviews, April 2019, Bentham Science Publishers

    Dr. Zahi Touma

  111. Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ)

    Article • The Journal of Rheumatology, February 2019, The Journal of Rheumatology

    Dr. Zahi Touma

  112. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies

    Article • Patient Related Outcome Measures, January 2019, Dove Medical Press

    Dr. Zahi Touma

  113. Disease course patterns in systemic lupus erythematosus

    Article • Lupus, December 2018, SAGE Publications

    Professor Murray B Urowitz, Dr. Zahi Touma

  114. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria

    Article • Arthritis & Rheumatology, November 2018, Wiley

    Dr Matteo Piga, Dr. Zahi Touma

  115. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

    Article • The Lancet, October 2018, Elsevier

    Dr. Zahi Touma

  116. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis

    Article • Seminars in Arthritis and Rheumatism, October 2018, Elsevier

    Dr. Zahi Touma

  117. Novel biological therapeutic approaches to cutaneous lupus erythematosus

    Article • Expert Opinion on Biological Therapy, September 2018, Taylor & Francis

    Dr. Zahi Touma

  118. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

    Article • The Journal of Rheumatology, September 2018, The Journal of Rheumatology

    Dr. Zahi Touma

  119. Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus

    Article • The Journal of Rheumatology, August 2018, The Journal of Rheumatology

    Dr. Zahi Touma

  120. Subcutaneous belimumab in the treatment of systemic lupus erythematosus

    Article • Immunotherapy, August 2018, Future Medicine

    Dr. Zahi Touma

  121. Psoriatic Arthritis Sonographic Enthesitis Instruments: A Systematic Review of the Literature

    Article • The Journal of Rheumatology, July 2018, The Journal of Rheumatology

    Dr. Zahi Touma

  122. Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome

    Article • The Journal of Rheumatology, July 2018, The Journal of Rheumatology

    Dr. Zahi Touma

  123. Monophasic Disease Course in Systemic Lupus Erythematosus

    Article • The Journal of Rheumatology, June 2018, The Journal of Rheumatology

    Dr. Zahi Touma

  124. FRI0208 Ankylosing spondylitis quality of life: defining minimal clinically important change

    Article • June 2018, BMJ

    Dr. Zahi Touma

  125. THU0423 Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome

    Article • June 2018, BMJ

    Dr. Zahi Touma

  126. Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans

    Article • Nature Immunology, May 2018, Springer Science + Business Media

    Dr. Zahi Touma

  127. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms

    Article • PLOS One, May 2018, PLOS

    Dr. Zahi Touma

  128. Minimal Clinically Important Difference

    Article • Rheumatic Disease Clinics of North America, May 2018, Elsevier

    Dr. Zahi Touma

  129. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index

    Article • Rheumatology, April 2018, Oxford University Press (OUP)

    Dr. Zahi Touma

  130. Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis

    Article • Seminars in Arthritis and Rheumatism, February 2018, Elsevier

    Dr. Zahi Touma

  131. Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus

    Article • Arthritis Care & Research, December 2017, Wiley

    Dr. Zahi Touma

  132. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments

    Article • Lupus Science & Medicine, December 2017, BMJ

    Dr. Zahi Touma

  133. Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus

    Article • JCR Journal of Clinical Rheumatology, September 2017, Wolters Kluwer Health

    Dr. Zahi Touma

  134. Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus

    Article • The Journal of Rheumatology, September 2017, The Journal of Rheumatology

    Dr. Zahi Touma

  135. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort

    Article • Seminars in Arthritis and Rheumatism, June 2017, Elsevier

    Dr. Zahi Touma

  136. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

    Article • Rheumatology International, March 2017, Springer Science + Business Media

    Dr. Zahi Touma

  137. Reply

    Article • Arthritis Care & Research, February 2017, Wiley

    Dr. Zahi Touma

  138. Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease

    Article • February 2017, Springer Science + Business Media

    Dr. Zahi Touma

  139. Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort

    Article • BioMed Research International, January 2017, Hindawi Publishing Corporation

    Dr. Zahi Touma

  140. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies

    Article • Arthritis Care & Research, December 2016, Wiley

    Dr. Zahi Touma

  141. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus

    Article • Lupus, August 2016, SAGE Publications

    Dr. Zahi Touma

  142. Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials

    Article • Expert Opinion on Biological Therapy, July 2016, Taylor & Francis

    Dr. Zahi Touma

  143. Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Article • Arthritis Care & Research, July 2016, Wiley

    Dr. Zahi Touma

  144. Systemic lupus erythematosus

    Article • Nature Reviews Disease Primers, June 2016, Springer Science + Business Media

    Dr. Zahi Touma

  145. FRI0307 Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Dr. Zahi Touma

  146. FRI0341 Do Patients with SLE at Onset Differ from Mimickers? A Comparison of Clinical and Serological Manifestations in A Multicenter Cohort To Inform The Development of New Classification Criteria for SLE: Table 1

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Dr. Zahi Touma

  147. Canadian Rheumatology Association Meeting, February 17-20, 2016. Introduction, Abstracts, Author Index

    Article • The Journal of Rheumatology, April 2016, The Journal of Rheumatology

    Dr. Zahi Touma

  148. Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study

    Article • The Journal of Rheumatology, April 2016, The Journal of Rheumatology

    Dr. Zahi Touma

  149. Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus

    Article • Lupus, February 2016, SAGE Publications

    Dr. Zahi Touma

  150. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus

    Article • Arthritis Research & Therapy, October 2015, Springer Science + Business Media

    Dr. Zahi Touma

  151. SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement

    Article • The Journal of Rheumatology, June 2015, The Journal of Rheumatology

    Dr. Zahi Touma

  152. OP0091 A Low Density Granulocyte Gene Expression Signature Distinguishes Between Active Patients with and Without Nephritis in Systemic Lupus Erythematosus (SLE)

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Dr. Zahi Touma

  153. SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Dr. Zahi Touma

  154. SAT0386 What is the Best Screening Test to Identify Lupus Patients with Cognitive Impairment in an Ambulatory Setting?

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Dr. Zahi Touma

  155. DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC

    Article • International Journal of Technology Assessment in Health Care, January 2015, Cambridge University Press

    Dr. Zahi Touma

  156. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus

    Article • Drug Design Development and Therapy, November 2014, Taylor & Francis

    Dr. Zahi Touma

  157. OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients?

    Article • Annals of the Rheumatic Diseases, June 2014, BMJ

    Dr. Zahi Touma

  158. Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment

    Article • The Journal of Rheumatology, January 2014, The Journal of Rheumatology

    Dr. Zahi Touma

  159. Outcome measures in systemic lupus erythematosus

    Article • Indian Journal of Rheumatology, December 2013, Medknow

    Dr. Zahi Touma

  160. Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

    Article • Current Rheumatology Reports, November 2013, Springer Science + Business Media

    Dr. Zahi Touma

  161. Development, Sensibility, and Reliability of the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease

    Article • The Journal of Rheumatology, September 2013, The Journal of Rheumatology

    Dr. Zahi Touma

  162. GRAPPA Trainees Symposium 2012: A Report from the GRAPPA 2012 Annual Meeting

    Article • The Journal of Rheumatology, August 2013, The Journal of Rheumatology

    Dr. Zahi Touma

  163. THU0197 Time to recovery from proteinuria in lupus nephritis patients receiving standard of care treatment

    Article • Annals of the Rheumatic Diseases, June 2013, BMJ

    Dr. Zahi Touma

  164. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website

    Article • The Journal of Rheumatology, May 2013, The Journal of Rheumatology

    Dr. Zahi Touma

  165. Skin Nontuberculous Mycobacterial Infection in Systemic Lupus Erythematosus: An Unusual Skin Infection Mimicking Lupus Vasculitis

    Article • Seminars in Arthritis and Rheumatism, April 2013, Elsevier

    Dr. Zahi Touma

  166. Vaccination and auto-immune rheumatic diseases

    Article • Current Opinion in Rheumatology, March 2013, Wolters Kluwer Health

    Dr. Zahi Touma

  167. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions

    Article • Expert Opinion on Biological Therapy, January 2013, Informa Healthcare

    Dr. Zahi Touma

  168. The Assessment of Disease Activity in Rheumatic Diseases

    Article • International Journal of Rheumatology, January 2013, Hindawi Publishing Corporation

    Dr. Zahi Touma

  169. Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website

    Article • The Journal of Rheumatology, November 2012, The Journal of Rheumatology

    Dr. Zahi Touma

  170. SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years

    Article • Lupus, October 2012, SAGE Publications

    Dr. Zahi Touma

  171. Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50

    Article • Arthritis Research & Therapy, September 2012, Springer Science + Business Media

    Dr. Zahi Touma

  172. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months

    Article • Rheumatology, June 2012, Oxford University Press (OUP)

    Dr. Zahi Touma

  173. Does the change in season affect disease activity in patients with psoriatic arthritis?

    Article • Annals of the Rheumatic Diseases, April 2012, BMJ

    Dr. Zahi Touma

  174. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients

    Article • Rheumatology, November 2011, Oxford University Press (OUP)

    Dr. Zahi Touma

  175. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes

    Article • Arthritis Care & Research, September 2011, Wiley

    Dr. Zahi Touma

  176. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials

    Article • The Journal of Rheumatology, September 2011, The Journal of Rheumatology

    Dr. Zahi Touma

  177. Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus?

    Article • The Journal of Rheumatology, July 2011, The Journal of Rheumatology

    Dr. Zahi Touma

  178. Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire

    Article • BMC Medical Research Methodology, April 2011, Springer Science + Business Media

    Dr. Zahi Touma

  179. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A Reliable Index for Measuring Improvement in Disease Activity

    Article • The Journal of Rheumatology, February 2011, The Journal of Rheumatology

    Dr. Zahi Touma

  180. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation

    Article • Lupus, January 2011, SAGE Publications

    Dr. Zahi Touma

  181. Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50

    Article • The Journal of Rheumatology, December 2010, The Journal of Rheumatology

    Dr. Zahi Touma

  182. Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time

    Article • The Journal of Rheumatology, November 2010, The Journal of Rheumatology

    Dr. Zahi Touma

  183. Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis

    Article • The Journal of Rheumatology, October 2010, The Journal of Rheumatology

    Dr. Zahi Touma

  184. TNF Polymorphisms in Patients with Behçet Disease: A Meta-analysis

    Article • Archives of Medical Research, February 2010, Elsevier

    Dr. Zahi Touma

  185. SLEDAI-2K for a 30-day window

    Article • Lupus, November 2009, SAGE Publications

    Dr. Zahi Touma

  186. Successful treatment of cardiac involvement in dermatomyositis with rituximab

    Article • Joint Bone Spine, May 2008, Elsevier

    Dr. Zahi Touma

  187. Efficacité du rituximab dans le traitement d’une dermatomyosite avec atteinte cardiaque

    Article • Revue du Rhumatisme, May 2008, Elsevier

    Dr. Zahi Touma

  188. Long-Delayed Onset of Chest Wall Pain Defining a Patient With SAPHO Syndrome

    Article • JCR Journal of Clinical Rheumatology, December 2007, Wolters Kluwer Health

    Dr. Zahi Touma

  189. Oral bisphosphonates in treatment of transient osteoporosis

    Article • Clinical Rheumatology, October 2007, Springer Science + Business Media

    Dr. Zahi Touma

  190. Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T

    Article • Lupus, July 2007, SAGE Publications

    Dr. Zahi Touma

  191. The use of TNF-α blockers in Cogan’s syndrome

    Article • Rheumatology International, June 2007, Springer Science + Business Media

    Dr. Zahi Touma

  192. Family history of lymphoma and risk for solid tumors in patients with Sjogren’s syndrome

    Article • Rheumatology International, June 2007, Springer Science + Business Media

    Dr. Zahi Touma

  193. Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis

    Article • Future Rheumatology, April 2007, Future Medicine

    Dr. Zahi Touma

  194. Cardiac sarcoidosis responding to monotherapy with infliximab

    Article • Clinical Rheumatology, March 2007, Springer Science + Business Media

    Dr. Zahi Touma

  195. Endobronchial stenting for respiratory complications in relapsing polychondritis

    Article • Clinical Rheumatology, March 2006, Springer Science + Business Media

    Dr. Zahi Touma

  196. Successful treatment of Sjogren's syndrome with rituximab

    Article • Scandinavian Journal of Rheumatology, January 2006, Taylor & Francis

    Dr. Zahi Touma

  197. Successful retreatment with infliximab in patients with prior severe infusion reactions

    Article • Clinical Rheumatology, October 2005, Springer Science + Business Media

    Dr. Zahi Touma

  198. Response of deep cutaneous vasculitis to infliximab

    Article • Journal of the American Academy of Dermatology, August 2005, Elsevier

    Dr. Zahi Touma

  199. Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept

    Article • Rheumatology, May 2005, Oxford University Press (OUP)

    Dr. Zahi Touma, Souha Kanj